Study on explaining cancer drug benefits and risks
Part of Cancer clinical trials.
This study looks at how to explain the benefits and risks of new cancer drugs in a way that is easier to understand. It helps researchers learn how to communicate better with patients like you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You are fluent in English.
- You live in the United States.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study asks people who have or have had cancer to share their thoughts on how much a cancer drug may extend life. It aims to understand patient expectations about survival benefits.
This study surveys adults with cancer experience about how they value new cancer drugs, helping doctors better communicate treatment options. Your responses could improve how benefits and risks are explained to future patients.
This study tests a digital tool that uses pictures and simple visuals to help you understand your cancer treatment options. The goal is to make the experience better for you, your family, and your doctors.
This study looks at how doctors and patients talk about clinical trials, with the goal of improving conversations for everyone involved. If you join, you'll fill out questionnaires about your experiences.
This British Columbia study looks at how well different cancer treatments work in real life when doctors aren't sure which option is best. You and your doctor would choose a treatment, and researchers will track your results to help others.
This study looks at how teens and young adults with tough-to-treat cancers, and their families, want to hear news about their cancer. It will help doctors learn the best ways to share information during check-ups and scans.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.